Gemini Therapeutics (GMTX) Competitors $53.07 +1.65 (+3.21%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, NUVL, and LEGNShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors Roivant Sciences Revolution Medicines Verona Pharma BridgeBio Pharma Elanco Animal Health Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Legend Biotech Roivant Sciences (NASDAQ:ROIV) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Which has more risk & volatility, ROIV or GMTX? Roivant Sciences has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Do analysts rate ROIV or GMTX? Roivant Sciences presently has a consensus price target of $17.50, indicating a potential upside of 55.14%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, ROIV or GMTX? Roivant Sciences has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M263.94$4.35B-$0.25-45.12Gemini TherapeuticsN/AN/A-$71.87M-$1.00-53.07 Does the media prefer ROIV or GMTX? In the previous week, Roivant Sciences had 13 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Roivant Sciences and 0 mentions for Gemini Therapeutics. Roivant Sciences' average media sentiment score of 0.71 beat Gemini Therapeutics' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Overall Sentiment Roivant Sciences Positive Gemini Therapeutics Neutral Does the MarketBeat Community believe in ROIV or GMTX? Roivant Sciences received 37 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 78.87% of users gave Roivant Sciences an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5678.87% Underperform Votes1521.13% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Is ROIV or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Gemini Therapeutics N/A -38.78%-35.88% Do insiders and institutionals hold more shares of ROIV or GMTX? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryRoivant Sciences beats Gemini Therapeutics on 14 of the 18 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.30B$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-53.078.7827.1220.06Price / SalesN/A255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book18.366.557.064.70Net Income-$71.87M$143.93M$3.23B$247.88M7 Day Performance12.15%3.84%2.86%2.63%1 Month Performance19.96%11.20%9.07%6.36%1 Year Performance36.60%4.18%31.45%14.05% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$53.07+3.2%N/A+33.6%$2.30BN/A-53.0730ROIVRoivant Sciences2.3781 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.4448 of 5 stars$40.65+3.2%$67.08+65.0%+4.5%$7.57B$742K-11.32250Positive NewsVRNAVerona Pharma2.3658 of 5 stars$84.10+3.6%$82.13-2.3%+573.5%$6.82B$118.54M-43.8030Trending NewsAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.6239 of 5 stars$35.46+3.5%$57.09+61.0%+42.1%$6.73B$127.42M-12.44400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionELANElanco Animal Health1.1137 of 5 stars$13.440.0%$15.17+12.9%-22.3%$6.67B$4.43B33.599,800Positive NewsGRFSGrifols3.6544 of 5 stars$8.30-0.1%N/A+28.4%$5.71B$7.21B7.0926,300TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.80-1.1%$22.00+31.0%N/A$5.68B$783.21M0.00N/APositive NewsTGTXTG Therapeutics2.9618 of 5 stars$35.75+1.8%$40.80+14.1%+137.3%$5.68B$386.39M-357.46290Positive NewsAnalyst RevisionNUVLNuvalent2.4074 of 5 stars$77.18+3.4%$115.50+49.7%-2.7%$5.54BN/A-22.2440Positive NewsLEGNLegend Biotech3.0745 of 5 stars$29.32+1.3%$76.20+159.9%-17.3%$5.39B$728.30M-30.861,070Trending NewsShort Interest ↑Analyst Revision Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Verona Pharma Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Grifols Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMTX Stock Free GMTX Stock Alerts